Eli Lilly’s Taltz and Zepbound Combo Delivers Superior Results in Landmark Psoriatic Arthritis Trial

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the long term. On January 8, Eli Lilly announced ...
Rheumatology Advisor

Tirzepatide Added to Ixekizumab Improves Outcomes in Patients With PsA

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.
Healio

Lilly: Taltz plus Zepbound superior to monotherapy for psoriatic arthritis, weight loss

Combination therapy with ixekizumab and tirzepatide bested monotherapy with ixekizumab alone in both psoriatic arthritis and ...
GlobalData on MSN

Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study

These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.
Medical Dialogues

Ixekizumab and Tirzepatide combo Improves PsA Control and Weight Loss, suggests study

The TOGETHER-PsA study shows that combining ixekizumab with tirzepatide leads to significantly better psoriatic arthritis ...